BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
Friday, 29 August 2025 ()
BeOne Medicines Ltd. (NASDAQ:ONC) (formerly BeiGene) on Friday released topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, an investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Brutonβsβ¦
|
||||
You Might Like |
||||
